Soriano LJ, Rojas AP

Language: English
References: 5
Page: 1-2
PDF size: 169.75 Kb.

Text Extraction

In December 2019, a novel coronavirus designated SARS-CoV-2 was identified in Wuhan (China). This one has caused an international outbreak of respiratory illness termed COVID-19. Initially, most infected people reported exposure to a large seafood and wet animal market in Wuhan, indicating a possible animal-to-human transmission; current data has demonstrated that person-to-person transmission is the most important way of spread. On 30 January 2020, the WHO declared the COVID19 outbreak as a public health emergency of international concern. At the time of preparing this manuscript the WHO reported 372 757 confirmed cases and 16 231 deaths in more than 180 countries. Currently, no therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. Several pre-existing and potencial drugs candidates including chloroquine, remdesivir, lopinavir and ritonavir have been considered.

REFERENCES

1. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-and update on the status. Military Med Research. [internet] 2020 March 16 [cited 1 April 2020];7:11. Available from: http://www.dx.doi.org/10.1186/s40779-020-00240-0

2. Gao J, Tian Z, Yang X. Breakthrough:chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends [internet] 2020 Feb 19 [cited 1 April 2020]. Available from: http://www.dx.doi.org/10.5582/bst.2020.01047

3. Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, et al. Arguments in favour of remdesivir for treating SARS/CoV/2 infections. Int J Antimicrob Agents. [internet] 2020 March 16 [cited 1 April 2020]. Available from: http://www.dx.doi.org/10.1016/j.ijantimicag.2020.105933

4. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. New Engl J Med. [internet] 2020 Jan 31 [cited 1 April 2020]. Available from: http://www.dx.doi.org/10.1056/NEJMoa2001191

5. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. New Engl J Med. [internet] 2020 March 18 [cited 1 April 2020]. Available from: http://www.dx.doi.org/10.1056/NEJMoa2001282